

Remarks

Claims 65-68 stand rejected under 35 U.S.C. §112 as not being enabled. The Applicants respectfully submit that the rejection is now moot with respect to Claims 66-68 in view of their cancellation. Withdrawal of that portion of the rejection is respectfully requested.

The rejection acknowledges that the Specification enables the use of RGTA 1112 and 1113 (CM₂DPheS₂ and CM₃DTyrS₂). The Applicants have amended Claim 65 so that it now recites a process for treating fibroses comprising administering a therapeutically effective amount of a pharmaceutical composition comprising at least one biocompatible polymer selected from the group consisting of RGTA 1112 (CM₂DPheS₂) and RGTA 1113 (CM₃DTyrS₂). The Applicants accordingly respectfully submit that Claim 65 is fully enabled as acknowledged in the rejection. Withdrawal of the rejection of Claim 65 is respectfully requested.


Claims 65, 67 and 68 stand rejected under 35 U.S.C. §112 as hypothetically failing to comply with the written description requirement. In particular, the rejection states that Claim 65 contains new matter. Claim 65 has been amended as noted above. Therefore, the new matter issue has been resolved.

Claims 67 and 68 are said to comprise new matter. However, those claims have been cancelled and the rejection is now moot. Withdrawal of the rejection of Claims 65, 67 and 68 is respectfully requested.

Claims 67 and 68 stand rejected under 35 U.S.C. §112 as being indefinite. Those claims have been cancelled thereby rendering that rejection moot. Withdrawal of the rejection is respectfully requested.

In light of the foregoing, the Applicants respectfully submit that the entire Application is in condition for allowance, which is respectfully requested.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC/vbm
(215) 656-3381